Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients
Crossref DOI link: https://doi.org/10.1007/s40263-015-0251-1
Published Online: 2015-06-26
Published Print: 2015-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Johnson, Barbara H.
Bonafede, Machaon M.
Watson, Crystal
License valid from 2015-06-01